[1]
|
Park, C.H. and Lee, S.K. (2019) Gastroesophageal Reflux Disease. The Korean Journal of Gastroenterology, 73, 70-76. https://doi.org/10.4166/kjg.2019.73.2.70
|
[2]
|
蔡楠, 伏杭江, 刘政, 等. 胃食管反流病治疗研究进展[J]. 医学研究生学报, 2011, 24(7): 771-774.
|
[3]
|
李鹏, 张澍田. 胃食管反流病的流行病学研究和危险因素分析[J]. 北京中医药, 2008, 27(3): 169-170.
|
[4]
|
Nirwan, J.S., Hasan, S.S., Babar, Z.U., et al. (2020) Global Prevalence and Risk Factors of Gastro-Oesophageal Reflux Disease (GORD): Systematic Review with Meta-Analysis. Scientific Reports, 10, Article No. 5814. https://doi.org/10.1038/s41598-020-62795-1
|
[5]
|
屈坤鹏, 成晓舟. 我国部分地区胃食管反流病患病率的Meta分析[J]. 中华胃食管反流病电子杂志, 2015, 2(1): 34-44.
|
[6]
|
梁东飞, 贾子亮, 刘红国, 等. 胃食管反流病患者的流行病学分析[J]. 河北医药, 2023, 45(12): 1889-1891, 1897.
|
[7]
|
Que, J., Garman, K.S., Souza, R.F., et al. (2019) Pathogenesis and Cells of Origin of Barrett’s Esophagus. Gastroenterology, 157, 349-364.e1. https://doi.org/10.1053/j.gastro.2019.03.072
|
[8]
|
Chen, J. and Brady, P. (2019) Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment. Gastroenterology Nursing, 42, 20-28. https://doi.org/10.1097/SGA.0000000000000359
|
[9]
|
刘云, 于洪波. 胃食管反流病发病机制及治疗的研究进展[J]. 中国当代医药, 2019, 26(6): 23-25.
|
[10]
|
黄益洲, 刘杰, 汪薇, 等. 肥胖胃食管反流病患者的食管动力特征和质子泵抑制剂疗效分析[J]. 胃肠病学, 2022, 27(2): 70-74.
|
[11]
|
张丽丽, 戴启芸. 胃食管反流病影响因素及中医证型分布分析[J]. 浙江临床医学, 2021, 23(3): 390-392.
|
[12]
|
Gralnek, I.M., Dulai, G.S., Fennerty, M.B., et al. (2006) Esomeprazole versus Other Proton Pump Inhibitors in Erosive Esophagitis: A Meta-Analysis of Randomized Clinical Trials. Clinical Gastroenterology and Hepatology, 4, 1452-1458. https://doi.org/10.1016/j.cgh.2006.09.013
|
[13]
|
Moayyedi, P., Santana, J., Khan, M., et al. (2011) WITHDRAWN: Medical Treatments in the Short Term Management of Reflux Oesophagitis. Cochrane Database of Systematic Reviews, No. 2, CD003244. https://doi.org/10.1002/14651858.CD003244.pub3
|
[14]
|
司小北, 蓝宇. 长期使用质子泵抑制剂的不良反应[J]. 药物不良反应杂志, 2015(3): 218-221.
|
[15]
|
杨奇, 蔡宇. 长期使用质子泵抑制剂对胃食管反流病患者胃泌素的影响[J]. 中国药物滥用防治杂志, 2023, 29(10): 1823-1825.
|
[16]
|
蔡仁颂, 杨维忠, 崔光锐, 等. 胃食管反流病患者质子泵抑制剂使用与胃癌发生风险的相关性分析[J]. 消化肿瘤杂志(电子版), 2022, 14(2): 191-194.
|
[17]
|
Fass, R. (2007) Proton-Pump Inhibitor Therapy in Patients with Gastro-Oesophageal Reflux Disease: Putative Mechanisms of Failure. Drugs, 67, 1521-1530. https://doi.org/10.2165/00003495-200767110-00001
|
[18]
|
Sifrim, D. and Zerbib, F. (2012) Diagnosis and Management of Patients with Reflux Symptoms Refractory to Proton Pump Inhibitors. Gut, 61, 1340-1354. https://doi.org/10.1136/gutjnl-2011-301897
|
[19]
|
张梦然, 庞铭歌. 伏诺拉生治疗胃食管反流病的疗效及安全性随机对照试验Meta分析[J]. 胃肠病学和肝病学杂志, 2023, 32(5): 551-557.
|
[20]
|
李正翔, 段蓉, 申慧明. 11个省市16家医疗机构应用富马酸伏诺拉生治疗胃食管反流病的研究[J]. 中国医院用药评价与分析, 2023, 23(3): 321-324.
|
[21]
|
Ashida, K., Sakurai, Y., Hori, T., et al. (2016) Randomised Clinical Trial: Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Healing of Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics, 43, 240-251. https://doi.org/10.1111/apt.13461
|
[22]
|
黄志豪, 林昱. 埃索美拉唑联合雷尼替丁治疗胃食管反流病夜间酸突破的疗效观察[J]. 中国实用医药, 2016, 11(10): 136-137.
|
[23]
|
Leowattana, W. and Leowattana, T. (2022) Potassium-Competitive Acid Blockers and Gastroesophageal Reflux Disease[J]. World Journal of Gastroenterology, 28, 3608-3619. https://doi.org/10.3748/wjg.v28.i28.3608
|
[24]
|
亚冰玉. 对比分析质子泵抑制剂与H2受体阻断剂在胃食管反流病中的效果[J]. 黑龙江医学, 2020, 44(12): 1664-1666.
|
[25]
|
Sandhu, D.S. and Fass, R. (2018) Current Trends in the Management of Gastroesophageal Reflux Disease. Gut and Liver, 12, 7-16. https://doi.org/10.5009/gnl16615
|
[26]
|
Fackler, W.K., Ours, T.M., Vaezi, M.F., et al. (2002) Long-Term Effect of H2RA Therapy on Nocturnal Gastric Acid Breakthrough. Gastroenterology, 122, 625-632. https://doi.org/10.1053/gast.2002.31876
|
[27]
|
丁黎葭, 陈世耀. 促动力药治疗胃食管反流病的循证评价和进展[J]. 胃肠病学, 2009, 14(10): 633-636.
|
[28]
|
李春杏, 朱元明, 刘桦, 等. 促动力药联合质子泵抑制剂与单独质子泵抑制剂治疗胃食管反流疾病疗效的荟萃分析[J]. 中国药学(英文版), 2021, 30(4): 347-356.
|
[29]
|
沈爱宗, 张圣雨, 苏丹, 等. 促胃肠动力药酒石酸西尼必利[J]. 药物不良反应杂志, 2019, 21(1): 50-54.
|
[30]
|
Forbes, N., Cooray, M., Al-Dabbagh, R., et al. (2016) Domperidone Prescribing Practices Exposed Patients to Cardiac Risk Despite a “Black Box” Warning: A Canadian Tertiary Care Center Study. Canadian Journal of Gastroenterology and Hepatology, 2016, Article ID: 2937678. https://doi.org/10.1155/2016/2937678
|
[31]
|
陈胜. 莫沙必利联合PPI埃索美拉唑治疗胃食管反流病效果观察[J]. 医学食疗与健康, 2020, 18(9): 83-84.
|
[32]
|
Calabrese, F., Poletti, V., Auriemma, F., et al. (2023) New Perspectives in Endoscopic Treatment of Gastroesophageal Reflux Disease. Diagnostics, 13, Article 2057. https://doi.org/10.3390/diagnostics13122057
|
[33]
|
胡海清, 令狐恩强. 胃食管反流病内镜治疗现状[J]. 中华胃肠内镜电子杂志, 2017, 4(1): 36-40.
|
[34]
|
Liu, P.P., Meng, Q.Q., Lin, H., et al. (2019) Radiofrequency Ablation Is Safe and Effective in the Treatment of Chinese Patients with Gastroesophageal Reflux Disease: A Single-Center Prospective Study. Journal of Digestive Diseases, 20, 229-234. https://doi.org/10.1111/1751-2980.12722
|
[35]
|
高岩, 邓宛青, 魏雪, 等. 中青年与老年胃食管反流病患者内镜射频治疗的疗效分析[J]. 中国医刊, 2023, 58(6): 626-629.
|
[36]
|
Shah, A. and Kim, M.P. (2023) Gastroesophageal Reflux Disease in 2023: When to Operate and Current Endoscopic Options for Antireflux Therapy. Thoracic Surgery Clinics, 33, 125-134. https://doi.org/10.1016/j.thorsurg.2023.01.010
|
[37]
|
令狐恩强, 王宇菲, 王潇潇. 内镜下贲门缩窄术治疗胃食管反流病的报道一例[J]. 中华腔镜外科杂志(电子版), 2013, 6(6): 468-469.
|
[38]
|
Li, X., Zhang, X.B., Hu, H.Q., et al. (2017) Effect and Safety of Peroral Endoscopic Cardial Constriction for Gastroesophageal Reflux Disease. Chinese Medical Journal, 130, 1749-1750. https://doi.org/10.4103/0366-6999.209898
|
[39]
|
张熠. 内镜下贲门缩窄术与腹腔镜Nissen胃底折叠术治疗胃食管反流病的效果对比[D]: [硕士学位论文]. 郑州: 河南大学, 2021.
|
[40]
|
Inoue, H., Ito, H., Ikeda, H., et al. (2014) Anti-Reflux Mucosectomy for Gastroesophageal Reflux Disease in the Absence of Hiatus Hernia: A Pilot Study. Annals of Gastroenterology, 27, 346-351.
|
[41]
|
自翔宇, 张跃文, 曹渊卿, 等. 内镜下抗反流黏膜切除术对胃食管反流病疗效及安全性的Meta分析[J]. 医学信息, 2023, 36(20): 83-88.
|
[42]
|
Ihde, G.M. (2020) The Evolution of TIF: Transoral Incisionless Fundoplication. Therapeutic Advances in Gastroenterology, 13. https://doi.org/10.1177/1756284820924206
|
[43]
|
Trad, K.S., Barnes, W.E., Prevou, E.R., et al. (2018) The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-Effective. Surgical Innovation, 25, 149-157. https://doi.org/10.1177/1553350618755214
|
[44]
|
Haseeb, M., Brown, J., Hayat, U., et al. (2023) Impact of Second-Generation Transoral Incisionless Fundoplication on Atypical GERD Symptoms: A Systematic Review and Meta-Analysis. Gastrointestinal Endoscopy, 97, 394-406.e2. https://doi.org/10.1016/j.gie.2022.11.002
|
[45]
|
胡志伟, 汪忠镐, 吴继敏. 胃食管反流病的外科手术治疗[J]. 外科理论与实践, 2021, 26(5): 399-403.
|
[46]
|
吴继敏. 胃食管反流病的外科治疗[J]. 中国医刊, 2023, 58(3): 240-243.
|
[47]
|
吴继敏, 陈冬. 胃食管反流病外科治疗术式的演变和展望[J]. 中华外科杂志, 2020, 58(9): 677-682.
|
[48]
|
秦鸣放, 赵宏志. 腹腔镜胃底折叠术治疗胃食管反流病372例[J]. 中华胸心血管外科杂志, 2011, 27(3): 144-147.
|
[49]
|
郭小平, 张弓剑, 王志, 等. 腹腔镜食管裂孔疝修补术联合胃底折叠术对胃食管反流病合并食管裂孔疝患者抗反流效果及生活质量的影响[J]. 中华疝和腹壁外科杂志(电子版), 2018, 12(6): 440-443.
|
[50]
|
黄涛, 刘春庆, 赵磊, 等. Nissen胃底折叠术和Toupet胃底折叠术治疗胃食管反流病合并重度食管炎的疗效对比[J]. 中国临床医生杂志, 2021, 49(3): 318-320.
|
[51]
|
Lee, Y., Tahir, U., Tessier, L., et al. (2023) Long-Term Outcomes Following Dor, Toupet, and Nissen Fundoplication: A Network Meta-Analysis of Randomized Controlled Trials. Surgical Endoscopy, 37, 5052-5064. https://doi.org/10.1007/s00464-023-10151-5
|
[52]
|
刘光帅. 食管裂孔疝修补联合Nissen、Dor胃底折叠术治疗食管裂孔疝合并胃食管反流病的临床疗效分析[D]: [硕士学位论文]. 长春: 吉林大学, 2024.
|
[53]
|
Li, G., Jiang, N., Chendaer, N., et al. (2023) Laparoscopic Nissen versus Toupet Fundoplication for Short-and Long-Term Treatment of Gastroesophageal Reflux Disease: A Meta-Analysis and Systematic Review. Surgical Innovation, 30, 745-757. https://doi.org/10.1177/15533506231165829
|